Study of two drugs for CD30+ T-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two targeted drugs, chidamide and brentuximab vedotin, for people with a type of T-cell lymphoma that has the CD30 protein. It is for patients who are older or not healthy enough for standard chemotherapy, and whose cancer has come back or not responded to previous treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 or older, or under 70 but not healthy enough for chemotherapy.
- You have a type of T-cell lymphoma that tests positive for CD30, and it has come back or not improved after at least one prior treatment.
- You have not had chidamide or brentuximab vedotin before.
- Your cancer can be seen on a PET/CT scan and has a spot at least 1.5 cm wide.
- Your heart, liver, kidneys, lungs, and blood counts are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (bendamustine, chidamide, and lenalidomide) for patients with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to see if this new combination can help when standard treatments have failed.
This trial tests a new combination of drugs for people with a type of lymphoma called EBV-positive DLBCL that has not been treated before. The goal is to see if adding brentuximab vedotin to the standard R-CHP chemotherapy can improve outcomes.
This study looks at how well a combination drug treatment (brentuximab vedotin plus chemotherapy) works for patients with rare T-cell lymphomas in real-world clinical practice in Spain. It focuses on patients receiving this as their first treatment.
This early-phase study tests a lymphoma treatment in adults whose diffuse large B-cell lymphoma (DLBCL) is “CD30-positive” and who didn’t respond well to first-line chemotherapy (like R-CHOP) or had an early relapse. It aims to see if the treatment can shrink the lymphoma and is safe enough to move forward.
This trial tests a combination of two targeted drugs, Chidamide and Duvalisib, for people with peripheral T-cell lymphoma or NK/T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this drug combination can help shrink or control the lymphoma.
This Phase 2 study tests pembrolizumab together with brentuximab for people whose T-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. It may help shrink the lymphoma and improve long-term control by boosting the immune system and targeting a protein called CD30.
Hear when a new CD30+ Peripheral T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.